Ahmedabad, 25th of February, 2026 : Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”), an innovation-led life-sciences company with an international presence, plans to launch Semaglutide Injection under the brand names – SEMAGLYNTM, MASHEMATM and ALTERMETM, upon Semaglutide patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and Obesity.1
A critical differentiator of Zydus’ Semaglutide offering will be its novel, indigenously developed drug-delivery system. Unlike existing treatments that require patients to purchase multiple single-dose pens as they titrate their dosage, Zydus plans to introduce an innovative, adjustable single-pen device. This technology allows patients to seamlessly select and administer varying dose strengths from a single unit, significantly enhancing patient adherence, maximizing convenience and drastically reducing the overall cost of therapy.
Speaking on the development Managing Director, Zydus Lifesciences Limited, Dr. Sharvil Patel said, “Zydus’ innovative offering of Semaglutide injection is a testament to our enduring commitment to patient-centric innovation. We are not just planning to bring a critical therapy to market, we are aiming to elevate the standard of care. By introducing a first-of-its-kind drug delivery mechanism in India, we plan to simplify the treatment. This leap in convenience will drive better long-term adherence and, ultimately, significantly improved clinical outcomes for patients.”
Zydus has exclusive rights to this novel device, which will be able to deliver all strengths approved for Type 2 Diabetes Mellitus and Obesity. The pen will also be reusable bringing in greater affordability for the patients.
Diabetes and Obesity are among the most significant health concerns in India, and GLP-1 based therapies have the potential to contribute effectively to managing this increasing public health burden. As per International Diabetes Federation, there are 8.9 crore adults with diabetes in India i.e. 10.5% of total adult population2. India is witnessing a rapid rise in obesity across all age groups. In adults, the prevalence increased by 91 per cent among women (from 12.6 per cent to 24.0 per cent) and 146 per cent among men (from 9.3 per cent to 22.9 per cent), indicating a nationwide health crisis.3
About Zydus Lifesciences Limited
Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com
About The Author
More Stories
Fortis Hospital Cunningham Road Marks 35 Years || Shri Dinesh Gundu Rao, Hon’ble Minister For Health & Family Welfare, Govt Of Karnataka, Graces Milestone Celebration As Chief Guest.
Marriott International Closes A Stellar Year In South Asia With Over 100 Deals Signed, Driving 143% Increase Over The Previous Year.
Tired Of Guessing What To Learn? Here Are 5 Skills Stacks You Need To Stand Out In Your Career : Linkedin.